Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.75 |
| ▸ | DRD2 | P14416 | 7/20 | 0.75 |
| ▸ | DRD4 | P21917 | 6/20 | 0.75 |
| ▸ | DRD3 | P35462 | 3/20 | 0.75 |
| ▸ | HRH1 | P35367 | 2/20 | 0.75 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.75 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.75 |
| ▸ | DRD1 | P21728 | 2/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.75 |
| ▸ | HTR3B | O95264 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21248895 | 0.89 | HRH4 (0.61) | CHRM1DRD2DRD4DRD3HRH1 | |
| SCHEMBL22073541 | 0.88 | CHRM1 (0.75) | CHRM1DRD2DRD4DRD3HRH1 | |
| SCHEMBL22146771 | 0.87 | DRD2 (0.77) | CHRM1DRD2DRD4DRD3HRH1 | |
| Clozapine SCHEMBL29283918 | 0.86 | DRD2 (0.95) | CHRM1DRD2DRD4DRD3HRH1 | |
| Clozapine SCHEMBL8397 | 0.86 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3HRH1 | |
| Clozapine SCHEMBL5501558 | 0.86 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3HRH1 | |
| Clozapine SCHEMBL29590817 | 0.86 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3HRH1 | |
| Clozapine SCHEMBL20876213 | 0.86 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3HRH1 | |
| Clozapine SCHEMBL29360001 | 0.86 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3HRH1 | |
| Clozapine SCHEMBL29433929 | 0.86 | DRD2 (1.00) | CHRM1DRD2DRD4DRD3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2010048264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1670427-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | disclosed |
| WO-2009002507-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INCORPORATED | 2005-09-01 | — | — | US | disclosed |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | COMBINATORX, INCORPORATED | 2005-08-25 | — | — | US | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005048927-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | CHRM1 3012/4885DRD2 4247/4885DRD4 4101/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CHRM1 1417/4885DRD2 59/4885DRD4 82/4885 |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | IL5, TNF, LTC4S | CHRM1 3454/4885DRD2 3820/4885DRD4 2733/4885 |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, CMA1, CCL11 | CHRM1 1439/4885DRD2 2151/4885DRD4 1628/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | CHRM1 3915/4885DRD2 3053/4885DRD4 2515/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | CHRM1 4670/4885DRD2 4506/4885DRD4 3322/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | CHRM1 4670/4885DRD2 4506/4885DRD4 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.